Regeneron Pharmaceuticals Inc (REGN)
What changed in recent filings
- Revenue +17% YoYQuarter ended Jun 30, 2026
- Products segment 52% → 38%Sep 30, 2024 → Jun 30, 2026
- Institutions — 1 new · 3 added · 2 reduced13F · as of end of 2026 Q2
- Free cash flow declined recentlyDec 31, 2025 → Jun 30, 2026
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Regeneron Pharmaceuticals Inc recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 30, 2026Revenue +16.7% YoY · EPS $12.23Released before the open: Jul 29 close → Jul 30 close, the stock moved +6.2% · over the same window, market +1.7% · sector -0.9%
- 26Q1Released Apr 29, 2026Revenue +19.0% YoY · EPS $6.75Released before the open: Apr 28 close → Apr 29 close, the stock moved -6.2% · over the same window, market +0.0% · sector -1.2%
- 25Q4Released Jan 30, 2026Revenue +2.5% YoY · EPS $7.87Released before the open: Jan 29 close → Jan 30 close, the stock moved -1.1% · over the same window, market -0.3% · sector +0.0%
- 25Q3Released Oct 28, 2025Revenue +0.9% YoY · EPS $13.62Released before the open: Oct 27 close → Oct 28 close, the stock moved +11.8% · over the same window, market +0.3% · sector -0.9%
The next earnings release is estimated around Oct 27, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Regeneron Pharmaceuticals Inc
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 6 → 2026 Q2: 6 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Regeneron Pharmaceuticals Inc
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)0.15% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.22% of portfolio · held as of 2019 Q1 or earlier
- Capital World Investors0.06% of portfolio · held as of 2020 Q3 or earlier
- Bridgewater Associates0.13% of portfolio · since 2021 Q2
- Dodge & Cox1.59% of portfolio · since 2021 Q4
- BlackstoneNew this quarterunder 0.01% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
A biotech holding antibody drugs such as the macular-degeneration drug Eylea and the atopic-dermatitis drug Dupixent.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Regeneron Pharmaceuticals Inc is classified under the Biotech & Health sector. See peers below.
Regeneron Pharmaceuticals Inc key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Regeneron Pharmaceuticals Inc vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
REGN revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $4.3B, +16.7% YoY.
The largest segment is Collaboration Revenue, 57.0% of revenue — a concentrated structure.
Recent revenue growth was led mainly by the Collaboration Revenue segment (about 97% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
REGN segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
1 quarter with a different segment breakdown was omitted (filing basis changed).
ETFs holding Regeneron Pharmaceuticals Inc
Per SEC N-PORT · 2026-06-30 · by weight · factual
REGN on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
REGN FAQ
What is Regeneron Pharmaceuticals Inc (REGN)?
A biotech holding antibody drugs such as the macular-degeneration drug Eylea and the atopic-dermatitis drug Dupixent.
What sector is Regeneron Pharmaceuticals Inc in?
Regeneron Pharmaceuticals Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Regeneron Pharmaceuticals Inc's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 9.3%, Operating margin 30.1%, Net margin 27.9%, ROE 14.4%, Debt-to-equity 0.06x. Definitions and interpretation are available on Stocklore.
What are Regeneron Pharmaceuticals Inc's main revenue segments?
The largest segment is Collaboration Revenue, about 57.0% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Regeneron Pharmaceuticals Inc (REGN) stock?
On Stocklore you can see REGN's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.